Blueprint Medicines Corp

Common Name

Blueprint Medicines

Country

United States

Sector

Healthcare

Industry

Biotechnology

Employees

682

Ticker

BPMC

Exchange

NASDAQ/NGS

Website

www.blueprintmedicines.com

Description

Blueprint Medicines Corp. is a biopharmaceutical company focused on developing targeted therapies to treat genomically defined cancers, rare diseases, and cancer immunotherapy. The company's primary p... Show more

Income Statement Balance Sheet Group Entities

Blueprint Medicines's Financial Statements Preview

Below are the financial statements of Blueprint Medicines, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.

Interested in getting early access to our real-time standardized financial datafeed?

Learn More

All figures in millions of USD	2024 as of 2024-12-31	2023 as of 2023-12-31
Assets	—	—
Current assets	—	—
Cash and cash equivalents	102.01^a	71.29^a
Marketable securities	513.47^a	639.36^a
Accounts receivable	75.8^a	42.83^a
Unbilled accounts receivable	1.81^a	0.35^a
Inventory	13.61^a	21.22^a
Prepaid expenses and other current assets	35.97^a	33.35^a
Total current assets	742.68^a	808.39^a
Marketable securities	248.45^a	56.53^a
Property and equipment, net	36.59^a	41.96^a
Operating lease right-of-use assets, net	64.18^a	73.69^a
Restricted cash	11.63^a	10.24^a
Equity investment	28.7^a	27.79^a
Other assets	47.59^a	30.65^a
Total assets	1,179.81^a	1,049.25^a
Liabilities and stockholders’ equity	—	—
Current liabilities	—	—
Accounts payable	6.79^a	4.71^a
Accrued expenses	133.09^a	127.99^a
Current portion of operating lease liabilities	13.35^a	11.93^a
Current portion of deferred revenue	2.01^a	0.81^a
Current portion of liabilities related to the sale of future royalties and revenues	61.65^a	39.2^a
Current portion of term loan	43.92^a	30.28^a
Total current liabilities	260.8^a	214.92^a
Operating lease liabilities, net of current portion	68.79^a	81.75^a
Deferred revenue, net of current portion	8.19^a	4.79^a
Liabilities related to the sale of future royalties and revenues, net of current portion	193.52^a	402.43^a
Term loan, net of current portion	343.05^a	208.54^a
Other long-term liabilities	6.79^a	6.21^a
Total liabilities	881.15^a	918.64^a
Stockholders’ equity	—	—
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0^a	0^a
Common stock, $0.001 par value; 120,000,000 shares authorized; 63,712,256 and 61,147,236 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	0.06^a	0.06^a
Additional paid-in capital	2,709.18^a	2,473.99^a
Accumulated other comprehensive loss	-3.55^a	-3.5^a
Accumulated deficit	-2,407.03^a	-2,339.94^a
Total stockholders’ equity	298.67^a	130.61^a
Total liabilities and stockholders’ equity	1,179.81^a	1,049.25^a

Download Data

Verified Sources Behind Blueprint Medicines’s Financial Fundamentals Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Blueprint Medicines’s data sources below and access millions more through our Disclosure Search.

a. Blueprint Medicines's 10-K 2024

Real-Time & Standardized Financials

Access Standardized Financial Statements within Minutes of Disclosure

Tracenable is building real-time standardized financial datafeeds and APIs covering global equities. Unlike limited and inconsistent XBRL parsing, our approach aims to deliver clean, comparable, and fully traceable data seconds after publication.

Could this solution support your investment or analytical workflows?

Explore Peer Companies

Welcome Back to Tracenable

Sign in to your account

Blueprint Medicines Corp

Blueprint Medicines's Financial Statements Preview

Verified Sources Behind Blueprint Medicines’s Financial Fundamentals Data

Access Standardized Financial Statements within Minutes of Disclosure

Explore Peer Companies

TG Therapeutics Inc

SpringWorks Therapeutics Inc

ADMA Biologics Inc

Axsome Therapeutics Inc

Iovance Biotherapeutics Inc

Insmed Inc